Ditchcarbon
  • Contact
  1. Organizations
  2. Merus N.V.
Public Profile
Pharmaceutical Preparation Manufacturing
NL
updated a month ago

Merus N.V. Sustainability Profile

Company website

Merus N.V., a pioneering biotechnology company headquartered in the Netherlands, focuses on the development of innovative bispecific antibody therapeutics. Founded in 2003, Merus has established itself as a leader in the biopharmaceutical industry, particularly in the fields of oncology and immunology. The company’s unique proprietary technology platform, known as the Biclonics® platform, enables the creation of bispecific antibodies that can simultaneously target multiple antigens, offering potential advantages in treating complex diseases. With a strong presence in Europe and North America, Merus has achieved significant milestones, including successful clinical trials and strategic partnerships with major pharmaceutical companies. The company’s commitment to advancing cancer treatment through its core products positions it as a notable player in the competitive biotech landscape, dedicated to improving patient outcomes and transforming therapeutic approaches.

DitchCarbon Score

How does Merus N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

28

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Merus N.V.'s score of 28 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.

48%

Let us know if this data was useful to you

Merus N.V.'s reported carbon emissions

Merus N.V., headquartered in the Netherlands, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Merus N.V. may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, it will be essential for Merus N.V. to consider developing and communicating its climate commitments to align with global standards and expectations.

How Carbon Intensive is Merus N.V.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Merus N.V.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Merus N.V.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Merus N.V. is in NL, which has a very low grid carbon intensity relative to other regions.

Merus N.V.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Merus N.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Merus N.V.'s Emissions with Industry Peers

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated about 17 hours ago

Crescendo Biologics Limited

GB
•
Research and development services (73)
Updated 4 days ago

Genmab

DK
•
Pharmaceutical Preparation Manufacturing
Updated about 16 hours ago

RenBio, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251106.5
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy